US0977021049 - Common Stock
BOLT BIOTHERAPEUTICS INC
NASDAQ:BOLT (4/25/2024, 7:00:01 PM)
After market: 1.2 +0.04 (+3.45%)1.16
-0.04 (-3.35%)
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 94 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of immunotherapies for the treatment of cancer. Its proprietary Boltbody ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. This approach creates products that work with a patient’s own immune system, resulting in anti-cancer efficacy with tolerability. Its first Boltbody ISAC is its BDC-1001 program, targeting a tumor antigen, HER2. BDC-1001 completed a dose-escalation trial and is advancing into multiple Phase II clinical trials. BDC-3042, its Dectin-2 agonist antibody program, is being developed to repolarize critical cells in the tumor microenvironment known as tumor-associated macrophages (TAMs) by targeting cell-surface receptors.
BOLT BIOTHERAPEUTICS INC
900 Chesapeake Drive
Redwood City CALIFORNIA 94063
P: 16506659295
CEO: Randall C. Schatzman
Employees: 94
Website: https://boltbio.com/
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bolt Biotherapeutics (NASDAQ:BOLT) just reported results for the fourth quarter...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study...
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...
Here you can normally see the latest stock twits on BOLT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: